Superluminal Medicines Inc.
- 04/09/2023
- Seed
- $33,000,000
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created.
Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability.
With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.
- Industry Biotechnology Research
- Website https://superluminalrx.com/
- LinkedIn https://www.linkedin.com/company/superluminalrx/about/
Related People
Ajay YekkiralaCo Founder
- Dynamic thought leader and serial inventor with over 17 years of industry and academic experience in life science drug discovery and development.
- Biotech entrepreneur with successful track record in raising capital and capacity to disrupt the CNS disease space.
- Solid team leadership and collaboration skills to build BD and scientific strategy by bringing together network of KOLs, SMEs and investors.